“Benefit of using renal sodium-glucose cotransporter inhibitors 2 (iSGLT-2) in patients with type 2 Diabetes Mellitus and Heart Failure” (2020) Electronic Journal Collection Health, 12(9), p. e4349. doi:10.25248/reas.e4349.2020.